- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-2094
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness ; volume:19 ; number:1 ; day:6 ; month:1 ; year:2022 ; pages:1-16 ; date:12.2022
Journal of neuroinflammation ; 19, Heft 1 (6.1.2022), 1-16, 12.2022
- Creator
-
Yates, Abi G.
Weglinski, Caroline M.
Ying, Yuxin
Dunstan, Isobel K.
Strekalova, Tatyana
Anthony, Daniel C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12974-021-02357-y
- URN
-
urn:nbn:de:101:1-2022042407112137327994
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yates, Abi G.
- Weglinski, Caroline M.
- Ying, Yuxin
- Dunstan, Isobel K.
- Strekalova, Tatyana
- Anthony, Daniel C.
- SpringerLink (Online service)
Other Objects (12)
TLR7/9 antagonist reduces HIV-1-induced immune activation
Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-inflammatory Disease
Deoxyguanosine is a TLR7 agonist
Quantum computing reduces systemic risk in financial networks
TLR7 signaling in human plasmacytoid dentritic cells
Characterization of TLR7-independent effects of Imidazoquinolines
Tickling the TLR7 to cure viral hepatitis
The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants
TLR7 activation in epilepsy of tuberous sclerosis complex
TLR7 and IgM: dangerous partners in autoimmunity
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
TLR7/9 antagonist reduces HIV-1-induced immune activation
Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-inflammatory Disease
Deoxyguanosine is a TLR7 agonist
Quantum computing reduces systemic risk in financial networks
TLR7 signaling in human plasmacytoid dentritic cells
Characterization of TLR7-independent effects of Imidazoquinolines
Tickling the TLR7 to cure viral hepatitis
The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants
TLR7 activation in epilepsy of tuberous sclerosis complex
TLR7 and IgM: dangerous partners in autoimmunity
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
TLR7/9 antagonist reduces HIV-1-induced immune activation
Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-inflammatory Disease
Deoxyguanosine is a TLR7 agonist
Quantum computing reduces systemic risk in financial networks
TLR7 signaling in human plasmacytoid dentritic cells
Characterization of TLR7-independent effects of Imidazoquinolines
Tickling the TLR7 to cure viral hepatitis
The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants
TLR7 activation in epilepsy of tuberous sclerosis complex
TLR7 and IgM: dangerous partners in autoimmunity
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers